Skip to content

Derivatives at other companies

Halozyme Therapeutics logo
Halozyme TherapeuticsHALO

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.6B+96.7%

Profitability

See full
Gross margin91.9%
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0.0×
Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DerivativeAssetsNoncurrent.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's derivatives.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ligand Pharmaceuticals's derivatives?
Ligand Pharmaceuticals (LGND) reported derivatives of $13.53M in Q1 2026.
How has Ligand Pharmaceuticals's derivatives changed year-over-year?
Ligand Pharmaceuticals's derivatives decreased by 25.0% year-over-year, from $18.03M to $13.53M.
What is the long-term trend for Ligand Pharmaceuticals's derivatives?
Over 2 years (2023 to 2025), Ligand Pharmaceuticals's derivatives has grown at a 110.4% compound annual growth rate (CAGR), from $3.53M to $15.63M.